You are here
Articles
Posted on Sunday, May 12, 2013 - 7:23pm
Susan Branford1,2,3, David T. Yeung1,2,4, David M. Ross2,4,5, Jodi A. Prime1, Chani R. Field1, Haley K. Altamura1, Alexandra L. Yeoman1, Jasmina Georgievski1, Bronte A. Jamison1, Stuart Phillis1, Brad Sullivan1...
Posted on Sunday, May 12, 2013 - 7:19pm
Min Tang1, Mithat Gonen2, Alfonso Quintas-Cardama3, Jorge Cortes3, Hagop Kantarjian3, Chani Field4, Timothy P. Hughes4, Susan Branford4, and Franziska Michor1
Posted on Friday, April 26, 2013 - 1:53pm
Blood First Edition Paper, prepublished online April 25, 2013; DOI 10.1182/blood-2013-03-490003
Posted on Wednesday, April 17, 2013 - 5:53pm
Michael Kaufman | March 26, 2013
'While WT1 is overexpressed in leukemias and other cancers, including myeloma, and breast, ovarian, and colorectal cancers, it is found in few healthy cells, which makes side effects...
Posted on Wednesday, April 17, 2013 - 4:13pm
Charles A. Schiffer, MD1 | October 12, 2012
Posted on Wednesday, April 17, 2013 - 4:01pm
Dave Levitan | April 12, 2013
Chronic myeloid leukemia (CML) patients treated with nilotinib(Drug information on nilotinib) had fewer treatment-emergent BCR-ABL mutations than those treated with imatinib(Drug...
Posted on Wednesday, April 17, 2013 - 3:21pm
Dave Levitan | April 16, 2013
A study of patients with chronic myeloid leukemia (CML) treated with imatinib found that chronic fatigue is the major factor that limits health-related quality of life (HRQOL).
Posted on Wednesday, April 17, 2013 - 3:19pm
By Leah Lawrence | April 15, 2013
A majority of patients on imatinib(Drug information on imatinib) for treatment of gastrointestinal stromal tumor (GIST) or chronic myelogenous leukemia (CML) had low or absent levels of...
Posted on Thursday, April 11, 2013 - 12:05pm
S Mustjoki1, K Auvinen2,10, A Kreutzman1,10, P Rousselot3, S Hernesniemi1, T Melo4, A-M Lahesmaa-Korpinen5, S Hautaniemi5, S Bouchet6, M Molimard6, R Smykla7, F Y Lee7, J Vakkila1, S Jalkanen2,8, M Salmi2,9 and K...
Posted on Friday, April 5, 2013 - 4:24pm
Pratap Neelakantan1, Gareth Gerrard1, Claire Lucas2, Dragana Milojkovic1, Philippa May1, Lihui Wang2, Christos Paliompeis1, Marco Bua1, Alistair Reid1, Katayoun Rezvani1, Stephen O'Brien3, Richard Clark2, John Goldman1...
Posted on Sunday, March 31, 2013 - 7:45pm
Trying to Calculate the Economic Value of Dasatinib or Nilotinib for Imatinib-Resistant CML
Published Online: Thursday, March 28, 2013
Although it is now standard practice to utilize the second-...
Posted on Wednesday, March 27, 2013 - 1:30am
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors
Massimo Breccia, Giuliana Alimena.
Posted on Wednesday, March 27, 2013 - 1:12am
Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Andreas Hochhaus1, Giuseppe Saglio2,...
Posted on Saturday, March 23, 2013 - 12:00pm
21 March 2013EMA/CHMP/178415/2013 Committee for Medicinal Products for Human Use (CHMP)
Summary of opinion1 (initial authorisation)
Iclusig
Ponatinib
On 21 March 2013, the Committee for Medicinal...
Posted on Friday, March 15, 2013 - 6:59pm
Is going for cure in chronic myeloid leukemia possible and justifiable?
- ‹ previous
- 11 of 29
- next ›